our products

WHO adds ravidasvir to HCV recommendation guidelines

09 Aug 2018

The World Health Organization has added ravidasvir as a future pangenotypic direct-acting antiviral to the list of recommended therapies in their Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C, according to a press release.

Read more

Curing hepatitis C at a fraction of the cost

24 Jul 2018

A new hepatitis C combination therapy has a 97% cure rate for patients and can be produced at a fraction of the cost of current treatments. Sally Turner finds out more about the potential impact of this highly effective, low-cost therapy.

Read more

Suivez notre série L’hépatite C, la grande oubliée

22 Jul 2018

On estime à 19 millions le nombre de personnes infectées en Afrique. Des traitements existent, mais leur coût et l’inertie des gouvernements retardent la prise en charge des malades.

Read more

Collaboration to provide affordable hepatitis C treatment in Latin America

03 Jun 2018

A new collaboration between pharmaceutical companies and non-profit organizations will manufacture

Read more

$300 HCV combination reaches 97% cure rates in Malaysia, Thailand

13 Apr 2018

PARIS — Using a new medication and generic sofosbuvir, researchers reached 97% sustained virologic response in patients with hepatitis C both with and without cirrhosis; in this exclusive video from the International Liver Congress 2018, Drugs for Neglected Diseases Initiative (DNDi) addresses the impact of this research.

Read more

Non-profit’s $300 hepatitis C cure as effective as $84,000 alternative

12 Apr 2018

Exclusive: 71 million people stand to benefit from reduced price treatment for virus which can lead to liver cirrhosis, cancer and death.

Read more

New affordable hepatitis C combination treatment shows 97 percent cure rate

12 Apr 2018

An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard-to-treat cases, according to interim results from the Phase II/III STORM-C-1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the International Liver Conference in Paris.

Read more

WTO, WHO, WIPO Symposium To Look At Innovative Technologies And UN SDGs

22 Jan 2018

Three major international organizations in Geneva dealing with health, trade and intellectual property rights will come together next month to look at how innovative technologies can help to achieve the UN Sustainable Development Goals related to health. [Note: this article has been updated.]

Read more

Pharmaniaga, Pharco and DNDi sign agreement to provide affordable hepatitis C treatment in Malaysia

13 Nov 2017

A collaboration agreement with Pharco to manufacture and supply a new hepatitis C treatment regimen to be sold for US $300 in the public sector in Malaysia.

Read more

Egypt wins acclaim for aggressive campaign against hepatitis C

09 Oct 2017

Egypt has the highest rate of hepatitis C in the world. Now the country has undertaken an aggressive campaign to stamp out the disease, both domestically and abroad.

Read more

Tour n' Cure: Egypt launches medical tourism campaign to eradicate hepatitis C

09 Oct 2017

After launching an aggressive campaign to fight the debilitating hepatitis C virus domestically, Egypt launched a program to help the estimated 71 million people afflicted with the disease worldwide.

Read more

Urgent action needed on Hepatitis C

31 Jul 2017

It’s not acceptable that 500,000 M’sians are infected with the disease but cannot afford treatment, when a total cure is available. WORLD Hepatitis Day fell on July 28. So it was timely that the alarming situation of Hepatitis C in Malaysia has been highlighted.

Read more

800,000 Egyptians treated for hepatitis C since January 2016

10 May 2017

More than 800,000 Egyptians have been cured from hepatitis C since January 2016 and 2020 will not see this country with one single Hepatitis C patient.

Read more

Pharco, MPP Ink Deal for Affordable HCV Therapy in High-Prevalence Countries

21 Apr 2017

The Medicines Patent Pool (MPP) inked a license and technology transfer agreement with Egyptian drug manufacturer Pharco Pharmaceuticals covering affordable supply of the late-clinical-stage pan-genotypic hepatitis C virus (HCV) drug ravidasvir (PPI-668) in certain low- and middle-income countries (LMICs) with  high hepatitis prevalence, including Russia, Ukraine, Egypt, and Iran.

Read more

Address to the Regional Committee for the Eastern Mediterranean, Sixty-third Session

03 Oct 2016

The President of Egypt announced last week that Egypt today has no waiting list for patients requesting treatment and the focus is now on prevention and case detection.

Read more

The curious case of generic Hep C drug sofosbuvir

16 May 2016

For more than a decade, an academic debate has raged among public health experts, the World Health Organsiation and governments on the capacity, cost effectiveness and the potential benefits of generic drug production in developing countries other than India and China.

Read more

$300 vs. $80,000: Low-cost cure for hepatitis C in the works

18 Apr 2016

A non-profit group is working to develop an affordable treatment for hepatitis C that will cost less than US$300 per patient – a tiny fraction of the $80,000 price tag currently charged by big drug makers to treat the liver infection.

Read more

Hepatitis C treatment for under $300 coming soon

13 Apr 2016

A hepatitis C treatment that costs less than $300 (£210) – a tiny fraction of the $80,000-plus price charged by major drugmakers – has been successfully tested in Egypt and is expected to be available within two years.

Read more

Curing Hepatitis C, in an Experiment the Size of Egypt

15 Dec 2015

A new approach tested in Egypt could become the blueprint for providing cutting-edge medicines to the poor.

Read more

Pharco Pharma reports 100% HCV-4 cure rate with Sovaldi/ravidasvir combo in late-stage study

16 Nov 2015

Pharco Pharma reports 100% HCV-4 cure rate with Sovaldi/ravidasvir combo in late-stage study.

Read more

Naia Limited Raises $5.3 Million in Series A Financing Led By Pharco Pharmaceuticals

19 Oct 2015

RICHMOND, Calif., Oct. 19, 2015 /PRNewswire/ -- Naia Limited, an international drug development company with Subsidiaries developing innovative, clinical-stage compounds for short bowel syndrome (SBS), non-alcoholic steatohepatitis (NASH) and Type 2 diabetes, today announced it has raised $5.3 million in a Series A financing led by existing investor and strategic partner, Pharco Pharmaceuticals. 

Read more

Naia Limited, New International Drug Development Company, Launches with Experienced Executive Team and Licensing Agreements for Rare and Metabolic Diseases Assets

05 Jan 2015

GREENBRAE, Calif.--(BUSINESS WIRE)--Naia Limited (Naia), an international drug development company that employs an innovative global strategy to clinically advance drug candidates, today announced its formation

Read more